Drug Trial Radar · NCT02966834
Dose Response Study of GSK2330672 for the Treatment of Pruritus in Participants With Primary Biliary Cholangitis
Last checked: Nov 20, 2026Latest source record: May 4, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
147
Actual
Start
Jan 11, 2017
Primary completion
Apr 15, 2020
Study completion Apr 15, 2020
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Nov 17, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is being conducted to evaluate the efficacy, safety and tolerability of GSK2330672 administration for the treatment of pruritus (itch) in participants with primary biliary cholangitis (PBC). Participants will receive either placebo or one of the 4 dose regimens of GSK2330672 (20 milligram \[mg\], 90 mg or 180 mg taken once daily or 90 mg twice daily). Participants on GSK2330672 will also receive placebo tablets to maintain blinding. The study has a prospectively defined adaptive design that will utilize interim data to further inform and potentially optimize the doses under investigation. Hence, additional dose regimen may be added during study. The total duration of a participant in the study will be up to 45 days of screening and 24 weeks of study including follow-up.
Conditions
- Cholestasis
Interventions
PlaceboDrug
GSK2330672 matching placebo will be supplied as white film-coated tablets.
GSK2330672Drug
GSK2330672 will be supplied in 2 dose strengths of 10 mg and 45 mg white film-coated tablets.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Change From Baseline at Week 16 in the Mean Worst Daily Itch ScoreTime frame: Baseline and Week 16
Locations
66 sites in 10 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Phoenix, Arizona
GSK Investigational Site
Sacramento, California
GSK Investigational Site
Miami, Florida
GSK Investigational Site
Novi, Michigan
GSK Investigational Site
Manhasset, New Jersey
GSK Investigational Site
New York, New York
GSK Investigational Site
Allentown, Pennsylvania
GSK Investigational Site
Dallas, Texas
GSK Investigational Site
Seattle, Washington
GSK Investigational Site
Camperdown, New South Wales, Australia
GSK Investigational Site
Herston, Queensland, Australia
GSK Investigational Site
Prahran, Victoria, Australia
GSK Investigational Site
Nedlands, Western Australia, Australia
GSK Investigational Site
Calgary, Alberta, Canada
GSK Investigational Site
Edmonton, Alberta, Canada
GSK Investigational Site
Winnipeg, Manitoba, Canada
GSK Investigational Site
London, Ontario, Canada
GSK Investigational Site
Toronto, Ontario, Canada
GSK Investigational Site
Montreal, Quebec, Canada
GSK Investigational Site
Clermont-Ferrand, France
GSK Investigational Site
Grenoble, France
GSK Investigational Site
Lille, France
GSK Investigational Site
Paris, France
GSK Investigational Site
Pessac, France
GSK Investigational Site
Hamburg, Germany
GSK Investigational Site
Erlangen, Bavaria, Germany
GSK Investigational Site
Homburg, Saarland, Germany
GSK Investigational Site
Bologna, Emilia-Romagna, Italy
GSK Investigational Site
Milan, Lombardy, Italy
GSK Investigational Site
Monza (MB), Lombardy, Italy
GSK Investigational Site
Florence, Tuscany, Italy
GSK Investigational Site
Padova, Veneto, Italy
GSK Investigational Site
Chiba, Japan
GSK Investigational Site
Fukui, Japan
GSK Investigational Site
Gunma, Japan
GSK Investigational Site
Hiroshima, Japan
GSK Investigational Site
Hokkaido, Japan
GSK Investigational Site
Kagawa, Japan
GSK Investigational Site
Kanagawa, Japan
GSK Investigational Site
Nagasaki, Japan
Showing 40 of 66 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.